… agonists act primarily on airway smooth muscle cells and are quintessential for adequate
asthma management… Notably, the current Global Initiative for Asthma (GINA) strategy document …

… part of all asthma treatment regimes in those with asthma. A … , past and present, actions and
side effects, future challenges … The β2-adrenoceptor (β2-AR) on airway smooth muscle cells …

… ) adrenoreceptor agonist, the treatment of asthma patients has … The inducted hypertension
and tachycardia (now we known to … between treatment groups in the asthma control and in the …

… synthetic compounds for the treatment of asthma and COPD. In … AR agonist dual activities
represent the future direction toward the development of novel drugs in the treatment of asthma …

… The human β2-adrenoceptor is a 7-transmembrane receptor … and protein kinase after
β2-adrenoceptor activation. Beta-2 … of chronic obstructive pulmonary disease: current and future …

… agonist activity, did not impact airway responsiveness [Citation33]. However, after 28 days
of treatment, this inverse agonist … mild asthma, where extended nadolol treatment enhanced …

… Products for asthma and chronic obstructive pulmonary disease include β-2 receptor agonists,
… or would expand the range of drugs and diseases treatable by this route of administration. …

… into the application of β 2 -agonists in asthma, chronic obstructive pulmonary disease (COPD…
2 -agonist for the treatment of HF. Future studies should focus on the design of β 2 -agonists …

… They are considered as the most effective strategy for long-term asthma management. One
of the first inhaled corticosteroids Beclomethasone was recommended for use four times a …

… present understanding of the disease, and suggest possible future directions for COPD therapy…
monotherapy and as combination therapy with fluticasone for COPD and asthma patients. …